



October 4, 2024

BSE Limited
Floor 25, P. J. Towers
Dalal Street,
Mumbai - 400 001

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E)
Mumbai - 400 051

Scrip Code: 530019

Symbol: JUBLPHARMA

Dear Sirs,

Re.: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Further to our letter dated August 16, 2024, we wish to inform that Jubilant Biosys Innovative Research Services Pte Limited, Singapore ('JBIRSPL'), subsidiary of Jubilant Biosys Limited, a wholly owned subsidiary of the Company, Pierre Fabre SA for itself and entities of the Pierre Fabre Group ('Pierre Fabre') has, upon completion of the Consultation Process and the Hamon Law Process under French law, exercised its Put Option in terms of the "put option agreement", pursuant to which JBIRSPL would acquire 80% equity capital in Jasmin (new company incorporated in France, as a Société par Actions Simplifiée (SAS), 100% owned by Pierre Fabre). Jasmin shall acquire Pierre Fabre's R&D Centre (Including R&D Site and R&D activities) at Saint Julien, France upon closing of the transaction.

The aforesaid transaction is subject to finalization of definitive agreements, customary closing conditions. Relevant details are given in **Annexure-A** to this letter. The date and time of occurrence of event is 5.59 pm (IST) on Thursday, October 3, 2024.

We request you to take the same on record.

Thanking you,

Yours faithfully,
For Jubilant Pharmova Limited

Naresh Kapoor
Company Secretary
Encl.: As above

A Jubilant Bhartia Company

OUR VALUES



Jubilant Pharmova Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624

Details of Acquisition

Sr. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover, etc.	Jasmin (Registration no. 932735087), a new Société par Actions Simplifiée (SAS) incorporated by Pierre Fabre group in France to operate the research and preclinical development activities with discovery capabilities in Biologics and ADCs including (without limitation) various activities up to a drug candidate selection as are being currently carried out by Pierre Fabre at the research and development centre "Institut de Recherche Pierre Fabre" located Saint-Julien-en-Genevois, France. Jasmin will also acquire land and buildings and induct approximately 40 employees of R&D center of Pierre Fabre. Turnover - Not Applicable as newly formed company
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	No
3.	Industry to which the entity being acquired belongs	Drug Discovery for Biologics and ADCs
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Expanding the Jubilant Biosys service offerings in emerging technologies such as Biologics (Mabs) and Antibody Drug Conjugate. Establishing an R&D presence in Europe to better serve the European market and USA customers.

A Jubilant Bhartia Company

OUR VALUES



Jubilant Pharmova Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624

Sr. No.	Particulars	Details
		The acquisition will strengthen the overall company's position as leading global CRO services partner.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Foreign direct Investment approval by French Government for JBIRSPL to acquire 80% equity capital of Jasmin with 20% subscribed by Pierre Fabre. Approval of the City hall authority for transfer of Saint Julien site from Pierre Fabre to Jasmin.
6.	Indicative time period for completion of the acquisition	Approx. by end of December 2024
7.	Consideration - whether cash consideration or share swap or any other form and details of the same	Upto euro 4.4 million for 80% equity capital in Jasmin, infused by JBIRSPL over a period of 2 years.
8.	Cost of acquisition and/or the price at which the shares are acquired	See para 7 above
9.	Percentage of shareholding / control acquired and / or number of shares acquired	80% stake in Jasmin including Control
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Jasmin was incorporated as SAS under French Law on September 11, 2024, and is located in France. Last 3 years turnover - not applicable

A Jubilant Bhartia Company

OUR VALUES



Jubilant Pharmova Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624